Liisa Bayko was named Chief Financial Officer of Kalaris Therapeutics, Inc., effective July 20, 2026. As of November 6, 2026, Kalaris Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 10, 2026 to July 20, 2026, naming 5 appointments and 1 departure (Form 8-K, July 20, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Kalaris Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Liisa Bayko · Role: Chief Financial Officer · Effective: 2026-07-20 · 8-K, 2026-07-20
- · In / out: In · Person: Laurie Keating · Role: Director · Effective: 2026-08-01 · 8-K, 2026-07-06
- · In / out: Out · Person: Matthew Gall · Role: Chief Financial Officer · Effective: 2026-04-14 · 8-K, 2026-04-10
Kalaris Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-10 to 2026-07-20. They name 4 people, with 5 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Kalaris Therapeutics, Inc. files it.
Also on the record for Kalaris Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 26, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 5.69% of the class | 5%+ stakes | Source |
| May 22, 2026 | Stake report, Schedule 13D/A, by Samsara BioCapital, L.P. | 54.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13D/A, by Samsara BioCapital, L.P. | 56.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 5.7% of the class | 5%+ stakes | Source |
| December 22, 2025 | Stake report, Schedule 13D/A, by Samsara BioCapital, L.P. | 56.5% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by Invus Public Equities, L.P. | 1.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Kalaris Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Kalaris Therapeutics, Inc. and the records around it.
Kalaris Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Kalaris Therapeutics, Inc.
Get an email when Kalaris Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kalaris Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Kalaris Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kalaris Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-20 | In | Chief Financial Officer | 2026-07-20 | 8-K, 2026-07-20 | |
| 2026-07-20 | In | 8-K, 2026-07-20 | |||
| 2026-07-20 | In | Controller | 2026-07-27 | 8-K, 2026-07-20 | |
| 2026-07-06 | In | Director | 2026-08-01 | 8-K, 2026-07-06 | |
| 2026-07-06 | In | 2026-08-01 | 8-K, 2026-07-06 | ||
| 2026-04-10 | Out | Chief Financial Officer | 2026-04-14 | 8-K, 2026-04-10 |
Who leads Kalaris Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Laurie Keating, appointed, effective 2026-08-01 (filed 2026-07-06).
- Controller: Amy Vandekop, appointed, effective 2026-07-27 (filed 2026-07-20).
- Chief Financial Officer: Liisa Bayko, appointed, effective 2026-07-20 (filed 2026-07-20).
New leaders reset buying decisions — get the Full Report on Kalaris Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Kalaris Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Kalaris Therapeutics, Inc.Every change, in the filing's words
Appointed: Liisa Bayko, Chief Financial Officer, effective 2026-07-20
On July 16, 2026, the Board of Directors (the "Board") of Kalaris Therapeutics, Inc. (the "Company") appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the "Effective Date").
Appointed: Liisa Bayko
In addition, Ms. Bayko will serve as the Company's principal financial officer.
Appointed: Amy Vandekop, Controller, effective 2026-07-27
As a result, on July 16, 2026, the Board designated Amy Vandekop, the Company's Corporate Controller, as the Company's interim principal accounting officer, effective as of July 27, 2026.
- Prior to her appointment as Chief Financial Officer and Treasurer of the Company, Ms. Bayko, age 55, served as the Managing Director, Biotech Equity Research, of Evercore ISI, an investment bank, from August 2020 to December 2025.
- Prior to that, Ms. Bayko served as the Managing Director, Biotech Equity Research, of JMP Securities, an investment bank, from February 2011 to August 2020.
- Ms. Bayko holds an MBA from the Kellogg School of Management at Northwestern University, a M.Sc. from the University of Toronto and a B.Sc. from Queen's University.
- Pursuant to an employment agreement (the "Employment Agreement"), dated July 7, 2026, between the Company and Ms. Bayko governing the terms of her employment, Ms. Bayko will be paid an annualized base salary of $475,000 and will be eligible to receive an annual incentive bonus of up to 40.0% of her annualized base salary (the "Target Bonus") for each fiscal year, as determined by the Board, or a committee thereof, in its sole discretion.
- Also, as a condition to her employment and pursuant to the Employment Agreement, Ms. Bayko entered into a non-competition and non-solicitation agreement and an invention and non-disclosure agreement with the Company (the "Restrictive Covenant Agreements").
Appointed: Laurie Keating, Director, effective 2026-08-01
On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.
Appointed: Laurie Keating, effective 2026-08-01
The Board also elected Ms. Keating to serve as a member of the Audit Committee, effective as of August 1, 2026.
- Resignation of Director On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the "Company") of her decision to resign as a member of the Company's board of directors (the "Board"), effective immediately.
- With the resignation, Dr. Jovan-Embiricos also resigned as a member of the Audit Committee of the Board (the "Audit Committee").
- Dr. Jovan-Embiricos informed the Company that her resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
- Ms. Keating will serve as a Class I director with a term expiring at the 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier resignation, death or removal.
- In accordance with the policy, effective August 1, 2026 (the "Grant Date"), Ms. Keating will be granted an option to purchase 18,000 shares of the Company's common stock at an exercise price equal to the fair market value of the Company's common stock on the Grant Date, which option will vest in equal monthly installments from the Grant Date until the third anniversary of the Grant Date, subject to Ms. Keating's continued service.
- In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full.
Departing: Matthew Gall, Chief Financial Officer, effective 2026-04-14
On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the "Company") of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the "Separation Date").
- Appointment of Principal Financial Officer As a result of Mr. Gall's resignation, Brett Hagen, the Company's Chief Accounting Officer and principal accounting officer, will also serve as the Company's principal financial officer, effective as of the Separation Date.
- Brett Hagen, 53, has served as the Company's Chief Accounting Officer since January 2019.
- Prior to joining the Company, Mr. Hagen served as senior director finance and accounting at Eloxx Pharmaceuticals, Inc. from February 2018 to August 2018.
- Prior to that, Mr. Hagen served as vice president, finance and controller at Proteostasis Therapeutics, Inc. from May 2016 to December 2017.
- From July 2014 to May 2016, Mr. Hagen served as controller at BIND Therapeutics, Inc. Mr. Hagen received his B.A. from the University of Minnesota, a graduate degree in accounting from Wright State University and a graduate degree in finance from Suffolk University.
Tools for this story
Each opens in a new tab, filled in for Kalaris Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.